

Original Research Article

Forced degradation and stability indicating studies for Clomifene Citrate Tablet

ABSTRACT

Pharmaceutical medications must be stable to preserve their efficacy and safety over the period of their shelf lives. Studies on force degradation are crucial for identifying probable degradation pathways and identifying extreme stresses that may lead to the breakdown of the pharmaceutical product. This report offers a thorough analysis of the force degradation tests performed on Clomifene citrate tablets. Evaluation of the effects of several stress factors, including temperature, humidity, light, and mechanical forces, on the stability of clomifene citrate is the main goal. To replicate actual storage and handling situations, the study used stress testing criteria specified by the International Conference on Harmonization (ICH). According to the study, temperature and humidity have the biggest roles in the degradation of Clomifene citrate tablets. In this article the FDS was performed by using a stainless-steel column (250 mm x 4.6 mm) packed with *Butylsilane C4* (5 μ m) L26, detector 233nm, mobile phase; mobile Phase was prepared by mixing 550 volumes of methanol, 450 volumes of water and 3 volumes of triethylamine. Then adjust the pH to 2.5 with phosphoric acid. Flow rate; 1 mL/min. The quantification and hyphenation of the instrumental analysis were successfully accomplished using the developed method.

1. INTRODUCTION

A synthetic nonsteroidal substance called clomifene citrate has made a name for itself as a leading therapeutic treatment for female infertility. To ensure their therapeutic efficacy and patient safety, Clomifene citrate tablets must maintain their quality and stability throughout their shelf life, as is the case with any pharmaceutical product [1]. The resilience and vulnerability of pharmaceutical formulations under various stress circumstances are critically evaluated by force degradation studies, a type of stress testing [2]. The pharmaceutical sector depends greatly on force degradation studies to evaluate a medicinal substance's stability and potential breakdown mechanisms. It is a systematic study carried out under various stresses to imitate and speed up any degradation processes the drug substance may experience over the course of its shelf life. The study offers useful understanding of the mechanisms of degradation, impurity development, and degradation products, all of which are essential for guaranteeing the drug's safety, effectiveness, and quality [3].

The force degradation study tries to detect any potential degradation pathways and contaminants that may emerge by exposing the medicinal ingredient to stress conditions such as temperature, humidity, light, pH, and oxidative conditions [4]. It aids in comprehending the kinetics of degradation, the creation of degradation products, and the impact of various conditions on the stability of the therapeutic ingredient [5]. The study offers vital information for formula creation, packing issues, and creating suitable storage conditions. [6].

The degradation products created throughout the investigation are analyzed and characterized using analytical techniques such high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), spectroscopy, and other analytical methods. These methods provide structural clarification, quantification, and identification [7].

2. MATERIAL AND METHODS

2.1 Instruments

The chromatographic HPLC system (Agilent infinity-II 1260 series) was used for the development of stability indicating research and forced degradation for Clomifene Citrate Tablets. Other equipment used were oven, weight balance, Photo stability Chamber and Accelerated Stability Chamber [8].

2.2 Materials required

Clomifene Citrate (working standard) and Clomifene citrate Tablets were provided by Pacific Pharmaceuticals Ltd. Lahore, Pakistan. HPLC grade methanol were purchased from Mark, Germany. Analytical grade Hydrochloric acid, Hydrogen peroxide, Sodium Hydroxide and Triethylamine were purchased from sigma Aldrich chemicals, Mark Germany [9].

2.3 Chromatographic Conditions

The chromatographic analysis has been performed using a stainless-steel column 250 mm x 4.6 mm packed with *butylsilane* C4 (5 μ m) L26. The HPLC mobile phase were prepared by mixing 550 volumes of methanol, 450 volumes water and 3 volume Triethylamine [10]. Then the pH was adjusted to 2.5 with H₃PO₄. 233 nm detection wavelength and 25°C column temperature were used. HPLC flow rate was adjusted at 1.0 mL/min with 50 μ L injection volume [11].

2.4 Standard Preparation for Clomifene Citrate (working standard)

In a 100 mL flask, 50 mg of clomifene citrate (the working standard) was accurately weighed, 50 mL of mobile phase was added, and the mixture were sonicated for 15 minutes [12].

2.5 Hydrolysis

Water is reacted with a chemical at varying pH levels in a process known as hydrolysis, which is a typical degradative process [13]. During forced degradation, the drug interacted with the water in both acidic and basic conditions [14].

2.5.1 Acid Hydrolysis (0.1 M HCl)

2.5.1.1 Sample Solution-1 (No Acid, no base)

20 clomifene citrate pills were crushed to a fine powder. 100 mL of volumetric flask containing 305 mg of powder or 50 mg of clomifene citrate was weighed. After that, 50 mL of mobile phase was added. 15 minutes of sonication produced volume with mobile phase [15].




Fig. 1. Chromatogram for Soln-1 on Hydrolysis

2.5.1.2 Sample Solution-2 (0.1M HCl)

20 tablets of clomifene citrate were taken and fine powder was made. Then 305 mg of powder (equivalent to 50mg of clomifene citrate) was weighed in 100mL of volumetric flask. Then 50mL of 0.1 M HCl was added and sonicated for 15 minutes. Then volume was made with 0.1M HCl [16].




Fig. 2. Chromatogram for Soln-2 on Hydrolysis

2.5.1.3 Sample Solution-3 (0.1M NaOH)

20 tablets of clomifene citrate were taken and fine powder was made. Then 305 mg of powder (equivalent to 50mg of clomifene citrate) was weighed in 100mL volumetric flask. Then 50mL of 0.1 M NaOH was added and sonicated for 15 minutes. Then volume was made with 0.1M NaOH [17].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not soluble in 0.1M NaOH.




Fig. 3. Chromatogram for Soln-3 on Hydrolysis

2.5.1.4 Sample Solution-4 (0.1M HCl with No API)

Placebo sample of clomifene citrate tablets on lab scale were prepared by mixing excipients of 20 tablets. Then 255mg of powder (without API) were taken in 100mL flask and 50mL of 0.1M HCl was added and sonicated for 15 minutes. Then volume was made with 0.1M HCl [17].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not added.




Fig. 4. Chromatogram for Soln-4 on Hydrolysis

2.5.1.5 Sample Solution-5 (0.1M NaOH with No API)

Placebo sample of clomifene citrate tablets were prepared on lab scale by mixing excipients of 20 tablets. Then 255mg of powder (without API) was taken in 100mL flask and 50mL of 0.1M NaOH was added and sonicated for 15 minutes. Then volume was made with 0.1M NaOH [18].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not added.




Fig. 5. Chromatogram for Soln-5 on Hydrolysis

2.5.1.6 Sample solution-6 (0.1M NaOH, API without matrix)

50mg of Clomifene Citrate (working standard) was accurately weighed in 100mL flask. 50mL of 0.1M NaOH was added and sonicated for 15 minutes. Then volume was made with 0.1M NaOH [19].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not soluble in 0.1M NaOH.




Fig. 6. Chromatogram for Soln-6 on Hydrolysis

2.5.1.7 Sample solution-7 (0.1M HCl, API without matrix)

50mg of Clomifene Citrate (working standard) was weighed in 100mL flask. 50mL of 0.1M HCl was added and sonicated for 15 minutes. Then volume was made with 0.1M HCl [20].




Fig. 7. Chromatogram for Soln-7 on Hydrolysis

2.5.1.8 Sample Solution-8 (Neutral pH 7.0)

20 tablets of clomifene citrate were taken and fine powder was made. Then 305 mg of powder (equivalent to 50mg of clomifene citrate) was weighed in 100mL volumetric flask. Then 50mL of phosphate buffer solution (pH 7.0) was added and sonicated for 15 minutes. Then made volume with mobile phase [21].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not soluble in Neutral pH 7.0.




Fig. 8. Chromatogram for Soln-8 on Hydrolysis

2.5.1.9 Sample solution-9 (Neutral pH 7.0, API without matrix)

50mg of Clomifene Citrate (working standard) was accurately weighed in 100mL flask. 50mL of phosphate buffer solution (pH 7.0) was added and sonicated for 15 minutes. Then made volume with phosphate buffer solution pH 7.0 [22].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not soluble in Neutral pH 7.0.




Fig. 9. Chromatogram for Soln-9 on Hydrolysis

2.5.1.10 Sample Solution-10 (Neutral pH 7.0 with No API)

Placebo sample of clomifene citrate tablets on lab scale was prepared by mixing excipients of 20 tablets. Then 255mg of powder (without API) was taken in 100mL flask and 50mL of buffer solution (pH 7.0) was added and sonicated for 15 minutes. Then made volume with buffer solution pH 7.0 [23].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not added.




Fig. 10. Chromatogram for Soln-10 on Hydrolysis

2.6 Oxidation

Hydrogen peroxide is widely used to oxidize the pharmaceutical compounds in forced degradation investigations. 3.0% hydrogen peroxide solution was used for research on oxidation degradation [24].

2.6.1 Sample Solution-1 (without Oxidation)

20 tablets of clomifene citrate were taken and fine powder was made. Then 305 mg of powder (equivalent to 50mg of clomifene citrate) was weighed in a 100 mL volumetric flask. Then 50 mL of mobile phase was added and sonicated for 15 minutes. After that made volume of the flask with mobile phase [25].




Fig. 11. Chromatogram for Soln-1 on Oxidation

2.6.2 Sample Solution-2 (with Oxidation)

20 tablets of clomifene citrate were taken and fine powder was made. Then 305 mg of powder (equivalent to 50mg of clomifene citrate) was weighed in 100 mL volumetric flask. Then 50 mL of 3.0% v/v H₂O₂ was added and sonicated for 15 minutes [26]. Then made volume with 3.0% v/v H₂O₂.




Fig. 12. Chromatogram for Soln-2 on Oxidation

2.6.3 Sample Solution-3- Placebo (with Oxidation)

Placebo sample of clomifene citrate tablets on lab scale was prepared by mixing excipients of 20 tablets. Then 255 mg of powder (without API) was taken in 100 mL flask and 50mL of 3.0% v/v H₂O₂ was added and sonicated for 15 minutes. Then made volume with 3.0% v/v H₂O₂. [27]

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not added.




Fig. 13. Chromatogram for Soln-3 on Oxidation

2.7 Photolytic degradations

The photo stability analysis of pharmaceutical compounds must be evaluated to demonstrate that exposure to light does not affect in an unacceptably undesirable change [28]. When a pharmaceutical material is exposed to UV or fluorescent light, photo stability studies reveal the main degradants that are created. The range between 300 and 800 nm is considered to be the most common wavelength of light to cause photolytic degradation[29].

2.7.1 Sample Preparation-1

The Clomifene citrate tablet samples were exposed to light at a minimum of 200 W h/m² and 1.2 million lux hours. Fine powder was made out of 20 Clomifene citrate tablets. In a 100 mL volumetric flask, 305 mg of powder (or 50 milligrammes of clomifene citrate) was weighed. 50 mL of mobile phase was added and sonicated for 15 minutes [30].




Fig. 14. Chromatogram for Soln-1 on Photo degradation

2.7.2 Sample Preparation-2: (API without matrix)

50mg of Clomifene Citrate (working standard) was accurately weighed in 100 mL flask. 50mL of mobile phase was added and sonicated for 15 minutes. Then volume was made with mobile phase [30].




Fig. 15. Chromatogram for Soln-2 on Photo degradation

2.7.3 Sample Preparation-3 Placebo

Placebo sample of Clomifene citrate tablets on lab scale was prepared by mixing excipients of 20 tablets. Then 255 mg of powder (without API) was weighed in 100 mL flask. 50mL of mobile phase was added and sonicated for 15 minutes. Then made volume with mobile phase [31].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not added.




Fig. 16. Chromatogram for Soln-3 on Photo degradation

2.8 Thermal Degradation

It is best to undertake thermal deterioration under more difficult conditions (such dry heat and moist heat) [32].

2.8.1 Sample Preparations-1

Samples of clomifene citrate tablets were exposed to dry and wet heat to see the effect of temperature and humidity on the product. 20 tablets of clomifene citrate were taken and fine powder was made [33]. Then 305 mg of powder (equivalent to 50mg of clomifene citrate) was weighed in 100 mL volumetric flask. 50 mL of mobile phase was added and sonicated for 15 minutes and made volume with mobile phase [31].




Fig. 17. Chromatogram for Soln-1 on Thermal degradation

2.8.2 Sample Preparation-2: (API without matrix)

50mg of Clomifene Citrate (working standard) was accurately weighed in 100 mL flask. 50mL of mobile phase was added and sonicated for 15 minutes. Then made volume with mobile phase [34].




Fig. 18. Chromatogram for Soln-2 on Thermal degradation

2.8.3 Sample Preparation-3 Placebo

Placebo sample of Clomifene citrate tablets was prepared on lab scale by mixing excipients of 20 tablets. Then 255 mg of powder (without API) was taken in 100 mL flask. 50mL of mobile phase was added and sonicated for 15 minutes. Then made volume with mobile phase [35].

***Comment:** No Peak detection was observed because Clomifene Citrate (API) was not added.




Fig. 19. Chromatogram for Soln-3 on Thermal degradation

3. RESULTS AND DISCUSSION

The forced degradation study aimed to evaluate the susceptibility of Clomifene citrate tablets to various stress conditions, including acid, base, oxidation, photolysis, and thermal stress. The results revealed significant degradation under both acidic and alkaline conditions. These findings suggest that Clomifene citrate is sensitive to pH extremes, potentially leading to the formation of acidic and basic impurities during manufacturing and storage processes. The identification of these degradation products is essential in understanding the stability profile of the drug substance and guiding appropriate storage conditions.

3.1 Thermal Stress Analysis

Thermal stress testing was conducted to assess the impact of elevated temperatures on Clomifene citrate tablets. The results demonstrated a temperature-dependent degradation pattern, with higher temperatures leading to accelerated degradation. This observation indicates that appropriate temperature control during storage and transportation is crucial in maintaining the drug substance's stability. Additionally, the identification of thermal degradation products through chromatographic analysis provides valuable insights into potential degradation pathways, allowing for the formulation of more stable drug products.

3.2 Photolytic Degradation

The study also investigated the photolytic stability of Clomifene citrate tablets under exposure to UV light. The results revealed a moderate degree of degradation, with the drug substance being susceptible to photolysis. This indicates the need for light-protective packaging during storage to minimize photochemical degradation. The identification of photodegradation products is essential in understanding the drug's photosensitivity and in devising appropriate packaging solutions to ensure product quality and efficacy.

3.3 Stability Indicating Method Development

In the context of the stability-indicating study, a validated high-performance liquid chromatography (HPLC) method was developed to separate and quantify Clomifene citrate from its degradation products. The method exhibited excellent linearity, accuracy, and precision, making it suitable for stability testing and routine quality control. The use of a stability-indicating method is essential in accurately assessing the drug substance's stability over time and determining its shelf life.

Table 1. Conditions and results used for Hydrolysis

Degradation	Solution Types	Storage Conditions	Sampling interval (Days)	% age Degradation
Hydrolysis	Sample Solution-1	40 °C	1 st	1.62
			3 rd	2.83
			5 th	2.60
	Sample Solution-2	40 °C	1 st	14.07
			3 rd	16.08
			5 th	17.42
	Sample Solution-3	40 °C	1 st	-
			3 rd	-
			5 th	-
	Sample Solution-4	40 °C	1 st	-
			3 rd	-
			5 th	-
	Sample Solution-5	40 °C	1 st	-
			3 rd	-
			5 th	-
	Sample Solution-6	40 °C	1 st	-
			3 rd	-
			5 th	-
	Sample Solution-7	40 °C	1 st	15.56
			3 rd	16.15
			5 th	15.50
	Sample Solution-8	40 °C	1 st	-
			3 rd	-
			5 th	-
	Sample Solution-9	40 °C	1 st	-
			3 rd	-
			5 th	-
	Sample Solution-10	40 °C	1 st	-
			3 rd	-
			5 th	-




Fig. 20. Graphical Representation of Degradation for Clomifene Citrate during Hydrolysis Parameter.

Table 2. Conditions and results used for Oxidation (25 °C)

Degradation	Solution Types	Storage Conditions	Sampling interval (Days)	% age Degradation
Oxidation	Sample Solution-1	25 °C	1 st	0.90
			3 rd	2.48
			5 th	3.66
	Sample Solution-2	25 °C	1 st	10.51
			3 rd	12.30
			5 th	15.50
	Sample Solution-3	25 °C	1 st	-
			3 rd	-
			5 th	-




Fig. 21. Graphical Representation of Degradation for Clomifene Citrate during Oxidation (25°C) Parameter.

Table 3. Conditions and results used for Oxidation (40 °C)

Degradation	Solution Types	Storage Conditions	Sampling interval (Days)	% age Degradation
Oxidation	Sample Solution-1	40 °C	1 st	-
			3 rd	6.88
			5 th	10.88
	Sample Solution-2	40 °C	1 st	-
			3 rd	16.52
			5 th	15.24
	Sample Solution-3	40 °C	1 st	-
			3 rd	-
			5 th	-




Fig.22 . Graphical Representation of Degradation for Clomifene Citrate during Oxidation (45oC) Parameter.

Table 4. Conditions and results used for Photolysis

Degradation	Solution Types	Storage Conditions	Sampling interval (Days)	% age Degradation
Photolysis	Sample Solution-1	NLT 1.2 million lux hour	1 st	0.99
			3 rd	2.98
			5 th	3.83
	Sample Solution-2	NLT 1.2 million lux hour	1 st	0.80
			3 rd	5.04
			5 th	10.39
	Sample Solution-3	NLT 1.2 million lux hour	1 st	-
			3 rd	-
			5 th	-




Fig. 23. Graphical Representation of Degradation for Clomifene Citrate during Photolysis Parameter.

Table 5. Conditions and results used for Thermolysis

Degradation	Solution Types	Storage Conditions	Sampling interval (Days)	% age Degradation
Thermolysis	Sample Solution-1	50 °C / 75% Humidity	1 st	1.79
			3 rd	2.03
			5 th	3.48
	Sample Solution-2	50 °C / 75% Humidity	1 st	1.00
			3 rd	4.69
			5 th	7.97
	Sample Solution-3	50 °C / 75% Humidity	1 st	-
			3 rd	-
			5 th	-




Fig. 24. Graphical Representation of Degradation for Clomifene Citrate during Thermolysis Parameter.

4. CONCLUSION

The Clomifene citrate tablets force degradation experiment provided significant understandings of the stability and likely breakdown mechanisms of the formulation. The study included thorough testing under a range of stress conditions, such as temperature, humidity, light, and pH to demonstrate the tablets' susceptibility to disintegration. According to the study's findings, Clomifene citrate tablets degraded when exposed to acidic and alkaline environments as well as high temperatures. Understanding the stability profile of the formulation and choosing the best storage situations to preserve the consistency and potency of the drug depend heavily on this knowledge. According to the results, it is advised to store Clomifene citrate tablets in a cool, dry location away from harsh light and temperature changes to reduce the risk of product deterioration and assure product quality for the duration of the stated shelf life. Overall, the force degradation study contributed useful information to the knowledge of the stability of Clomifene citrate tablets, aiding in formulation optimization, packaging concerns, and making sure the efficacy and safety of the product.

REFERENCES

1. MISHRA S, PATEL C AND PATEL M. DEVELOPMENT AND VALIDATION OF STABILITY INDICATING CHROMATOGRAPHIC METHOD FOR SIMULTANEOUS ESTIMATION OF SACUBITRIL AND VALSARTAN IN PHARMACEUTICAL DOSAGE FORM. INT J APP PHARM. 2017; 9(5): 1-8.
2. MOUNIKA A S, DHACHINAMOORHTI D AND RAO C M P. DEVELOPMENT AND VALIDATION OF A NOVEL STABILITY INDICATING RP-HPLC METHOD FOR THE ESTIMATION OF ENTECAVIR IN TABLET FORMULATION. EUROPEAN JOURNAL OF BIOMEDICAL. 2017; 4(7): 176-80.
3. BHASKAR R, OLA M, AGNIHOTRI V, CHAVAN A AND GIRASE H. CURRENT TREND IN PERFORMANCE OF FORCED DEGRADATION STUDIES FOR DRUG SUBSTANCE AND DRUG PRODUCT'S. JOURNAL OF DRUG DELIVERY AND THERAPEUTICS. 2020; 10(2-S): 149-55.
4. BUGA I, UZOMA J I, REINDEL K, RASHID K, DIEP T, MCCARTAN P ET AL. PHYSICAL AND CHEMICAL STABILITY OF DEXAMETHASONE SODIUM PHOSPHATE IN INTRAVENOUS ADMIXTURES USED TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING. HOSPITAL PHARMACY. 2021; 56(4): 215-20.
5. CLOSOSKI G C, SOLDI R A, SILVA R M D, GUARATINI T, LOPES J N, PEREIRA P R ET AL. TENOFOVIR DISOPROXIL FUMARATE: NEW CHEMICAL DEVELOPMENTS AND ENCOURAGING IN VITRO BIOLOGICAL RESULTS FOR SARS-COV-2. JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY. 2020; 31: 1552-56.
6. HERMOSILLA J, PÉREZ-ROBLES R, SALMERÓN-GARCÍA A, CASARES S, CABEZA J, BONES J ET AL. COMPREHENSIVE BIOPHYSICAL AND FUNCTIONAL STUDY OF ZIV-AFLIBERCEPT: CHARACTERIZATION AND FORCED DEGRADATION. SCIENTIFIC REPORTS. 2020; 10(1): 2675.
7. LAMICHHANE S, DAS B, ADHIKARI R P AND JEYAPRAKASH M R. OVERVIEW OF FORCED DEGRADATION ANALYSIS FOR FDA APPROVED ANTIRETROVIRAL AGENTS: A REVIEW. JOURNAL OF YOUNG PHARMACISTS. 2022; 14(3).
8. GRABAREK A D, JISKOOT W, HAWA A, PIKE-OVERZET K AND MENZEN T. FORCED DEGRADATION OF CELL-BASED MEDICINAL PRODUCTS GUIDED BY FLOW IMAGING MICROSCOPY: EXPLORATIVE STUDIES WITH JURKAT CELLS. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2021; 167: 38-47.
9. ZHANG K, HAMIDIAN A H, TUBIĆ A, ZHANG Y, FANG J K, WU C ET AL. UNDERSTANDING PLASTIC DEGRADATION AND MICROPLASTIC FORMATION IN THE ENVIRONMENT: A REVIEW. ENVIRONMENTAL POLLUTION. 2021; 274: 116554.
10. AMBHORE J P, ADHAO V S, CHEKE R S, POPAT R R AND GANDHI S J. FUTURISTIC REVIEW ON PROGRESS IN FORCE DEGRADATION STUDIES AND STABILITY INDICATING ASSAY METHOD FOR SOME ANTIVIRAL DRUGS. GSC BIOLOGICAL AND PHARMACEUTICAL SCIENCES. 2021; 16(1): 133-49.
11. SHAH P, HADIYAL S AND DHADUK B B. STABILITY INDICATING LC-MS/MS METHOD AND VALIDATION OF SELEXIPAG IMPURITIES AND IDENTIFICATION OF ITS FORCE DEGRADATION PRODUCTS. BHAVIN B., STABILITY INDICATING LC-MS/MS METHOD AND VALIDATION OF SELEXIPAG IMPURITIES AND IDENTIFICATION OF ITS FORCE DEGRADATION PRODUCTS.
12. SHARMA A, COLES A, SEKARAN N K, PAGIDIPATI N J, LU M T, MARK D B ET AL. STRESS TESTING VERSUS CT ANGIOGRAPHY IN PATIENTS WITH DIABETES AND SUSPECTED CORONARY ARTERY DISEASE. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2019; 73(8): 893-902.
13. ZOGHLAMI A AND PAËS G. LIGNOCELLULOSIC BIOMASS: UNDERSTANDING RECALCITRANCE AND PREDICTING HYDROLYSIS. FRONTIERS IN CHEMISTRY. 2019; 7: 874.
14. EBEFORS K, WIENER R J, YU L, AZELOGLU E U, YI Z, JIA F ET AL. ENDOTHELIN RECEPTOR-A MEDIATES DEGRADATION OF THE GLOMERULAR ENDOTHELIAL SURFACE LAYER VIA PATHOLOGIC CROSSTALK BETWEEN ACTIVATED PODOCYTES AND GLOMERULAR ENDOTHELIAL CELLS. KIDNEY INTERNATIONAL. 2019; 96(4): 957-70.

15. FARIAS F F, MARTINS V A P, YANO H M, TRUJILLO L M AND PINTO E. FORCED DEGRADATION STUDIES TO IDENTIFY ORGANIC IMPURITIES IN PHARMACEUTICALS: A BRAZILIAN PERSPECTIVE. *REVISTA DE CIÊNCIAS FARMACÊUTICAS BÁSICA E APLICADA*. 2021; 42: 1-13.
16. PATEL S, VYAS V K AND MEHTA P J. A REVIEW ON FORCED DEGRADATION STRATEGIES TO ESTABLISH THE STABILITY OF THERAPEUTIC PEPTIDE FORMULATIONS. *INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS*. 2023; 29(2): 22.
17. PISE N P, PRABHU A AND RAHEJA R. *FORCED DEGRADATION STUDIES ON AGENTS OF THERAPEUTIC INTEREST*. IN *MEDICAL SCIENCES FORUM*. 2022. MDPI.
18. AL-HAKKANI M F. FORCED DEGRADATION STUDY WITH A DEVELOPED AND VALIDATED RP-HPLC METHOD FOR DETERMINATION OF CEFPODOXIME PROXETIL IN THE BULK AND FINISHED PHARMACEUTICAL PRODUCTS. *JOURNAL OF THE IRANIAN CHEMICAL SOCIETY*. 2019; 16(7): 1571-78.
19. PARAB M, SHIRSAT V A, KODGULE Y M AND KODGULE M. A RP-HPLC METHOD FOR THE ANALYSIS OF NEOSTIGMINE METHYLSULFATE AND PROCESS-RELATED IMPURITIES, FORCED DEGRADATION STUDIES, IN THE INJECTION FORMULATION. *INTERNATIONAL JOURNAL OF ANALYTICAL CHEMISTRY*. 2021; 2021: 1-14.
20. NOORBASHA K AND NURBASHA S. A NEW VALIDATED STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS QUANTIFICATION OF DOLUTEGRAVIR AND LAMIVUDINE IN BULK AND PHARMACEUTICAL DOSAGE FORM. *FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES*. 2020; 6: 1-10.
21. DHALAPE V M, KHADANGALE S T AND PINJARI R V. RP-HPLC METHOD VALIDATION FOR QUANTITATIVE ANALYSIS OF PEMETREXED DISODIUM HEMIPENTAHYDRATE. *RESEARCH JOURNAL OF PHARMACY AND TECHNOLOGY*. 2020; 13(8): 3685-89.
22. KANTHALE S B, THONTE S S AND MAHAPATRA D K. DEVELOPMENT OF VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR THE ESTIMATION OF GLECAPREVIR AND PIBRENTASVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM. *JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE*. 2019; 9(6): 052-60.
23. MURUGESAN A AND ANNAPURNA M. SIMPLE QUANTIFIED AND VALIDATED STABILITY INDICATING STRESS DEGRADATION STUDIES OF ORAL ANTI-DIABETIC AGENT DAPAGLIFLOZIN BY RP-HPLC METHOD. *INT J APP PHARM*. 2022; 14(1): 231-7.
24. SUTAR S V, YELIGAR V C AND PATIL S S. A REVIEW: STABILITY INDICATING FORCED DEGRADATION STUDIES. *RESEARCH JOURNAL OF PHARMACY AND TECHNOLOGY*. 2019; 12(2): 885-90.
25. SOLANKI R V, PATEL R B, PATEL R K AND SHETH R A. DEVELOPMENT AND VALIDATION OF FAST AND ROBUST STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF TOLPERISONE HYDROCHLORIDE AND ETORICOXIB IN PHARMACEUTICAL DOSAGE FORM. *INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION*. 2022; 12(1).
26. SURYAWANSHI D, JHA D K, SHINDE U AND AMIN P D. DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD OF CHOLECALCIFEROL IN BULK AND PHARMACEUTICAL FORMULATIONS: ANALYTICAL QUALITY BY DESIGN APPROACH. *JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE*. 2019; 9(6): 021-32.
27. DEODHE S T, DHABARDE D M, KAMBLE M A AND MAHAPATRA D K. NOVEL STABILITY INDICATING RP-HPLC METHOD FOR THE ESTIMATION OF PINAVERIUM BROMIDE IN TABLET FORMULATION: ASSAY DEVELOPMENT AND VALIDATION. *EURASIAN JOURNAL OF ANALYTICAL CHEMISTRY*. 2017; 12(2).
28. KATAKAM L N R, ETTABOINA S K AND DONGALA T. A SIMPLE AND RAPID HPLC METHOD FOR DETERMINATION OF PARABENS AND THEIR DEGRADATION PRODUCTS IN PHARMACEUTICAL DOSAGE FORMS. *BIOMEDICAL CHROMATOGRAPHY*. 2021; 35(10): E5152.
29. SAIDA S J, MANIKANDAN A, KALIYAPERUMAL M, RUMALLA C S, KHAN A A, JAYARAMAN V B ET AL. IDENTIFICATION, ISOLATION AND CHARACTERIZATION OF DOLUTEGRAVIR FORCED DEGRADATION PRODUCTS AND THEIR CYTOTOXICITY POTENTIAL. *JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS*. 2019; 174: 588-94.

30. ROBERTO DE ALVARENGA JUNIOR B AND LAJARIM CARNEIRO R. CHEMOMETRICS APPROACHES IN FORCED DEGRADATION STUDIES OF PHARMACEUTICAL DRUGS. MOLECULES. 2019; 24(20): 3804.
31. KOWTHARAPU L P, KATARI N K, SANDOVAL C A, MUCHAKAYALA S K AND REKULAPALLY V K. UNIQUE GREEN CHROMATOGRAPHY METHOD FOR THE DETERMINATION OF SEROTONIN RECEPTOR ANTAGONIST (ONDANSETRON HYDROCHLORIDE) RELATED SUBSTANCES IN A LIQUID FORMULATION, ROBUSTNESS BY QUALITY BY DESIGN-BASED DESIGN OF EXPERIMENTS APPROACH. JOURNAL OF SEPARATION SCIENCE. 2022; 45(10): 1711-26.
32. ASIM M, PARIDAH M T, CHANDRASEKAR M, SHAHROZE R M, JAWAID M, NASIR M ET AL. THERMAL STABILITY OF NATURAL FIBERS AND THEIR POLYMER COMPOSITES. IRANIAN POLYMER JOURNAL. 2020; 29: 625-48.
33. PANDEY K, SINGH C, VERMA S, SINGH A, JHA R, PORWAL O ET AL. DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR RELATED SUBSTANCES OF IMATINIB MESYLATE. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2022; 84(2).
34. VANKALAPATI K R, ALEGETE P AND BOODIDA S. STABILITY-INDICATING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF METFORMIN, LINAGLIPTIN, AND EMPAGLIFLOZIN IN BULK AND PHARMACEUTICAL DOSAGE FORM. BIOMEDICAL CHROMATOGRAPHY. 2021; 35(4): E5019.
35. CARJE A G, BALINT A, ION V, POP A L, MUNTEAN D-L, SABAU R ET AL. HPLC-UV METHOD APPROACH FOR THE ANALYSIS AND IMPURITY PROFILING OF CAPTOPRIL. STUD. UNIV. BABES-BOLYAI CHEM. 2019; 64(2): T1.

DEFINITIONS, ACRONYMS, ABBREVIATIONS

Here is the Definitions section. This is an optional section.

Term: Definition for the term